1 Abstract
Our main aim is to estimate the last day for COVID-19 outbreak in mainland China. We developed mathematical models to predict reasonable bounds on the date of end of the COVID-19 epidemics in mainland China with strong quarantine and testing measures for a sufficiently long time. We used reported data in China from January 20, 2020 to April 9, 2020. We firstly used a deterministic approach to obtain a formula to compute the probability distribution of the extinction date by combining the models and continuous-time Markov processes. Then we present the individual based model (IMB) simulations to compare the result by deterministic approach and show the absolute difference between the estimated cumulative probability distribution computed by simulations and formula. We provide the predictions of the last day of epidemic for different fractions f of asymptomatic infectious that become reported symptomatic infectious.
Key points
We conducted a study of the last day for COVID-19 outbreak in mainland China. By using a deterministic approach, we obtain a formula to compute the probability distribution of the extinction date.
We estimated the probability distribution of the extinction date by individual-based stochastic simulations and compared the results from two methods (simulations and formula).
Stochastic simulations were used to precisely estimate the cumulative probability distribution of the date of end of the epidemic.
We predict the last day of epidemic for different fractions f of asymptomatic infectious that become reported symptomatic infectious.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the National Natural Science Foundation of China (grant number: 11871007 (ZL)), NSFC and CNRS (Grant number: 11811530272 (ZL, PM)) and the Fundamental Research Funds for the Central Universities (ZL).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We use the data from WHO
